Protocatechualdehyde (Synonyms: Catechaldehyde; Protocatechuic aldehyde; Rancinamycin IV)

Name: Protocatechualdehyde
Brand: MedChemExpress
SKU: HY-N0295
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0295 Purity: 99.98%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Protocatechualdehyde (Catechaldehyde), a natural polyphenol compound isolated from the roots of radix Salviae Miltiorrhizae, is associated with a wide variety of biological activities and has been widely used in medicine as an antioxidant, anti-aging, an antibacterial and anti-inflammatory agent.

For research use only. We do not sell to patients.

Protocatechualdehyde Chemical Structure

CAS No. : 139-85-5

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Protocatechualdehyde:

Protocatechualdehyde (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 22	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25710081]
A549	IC₅₀	3.1 μM Compound: 17	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 24359303]
A549	GI₅₀	42 μM Compound: 2	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
B16-4A5	IC₅₀	17 μM Compound: 36	Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs	[PMID: 20189399]
Bel-7402	IC₅₀	3.7 μM Compound: 17	Cytotoxicity against human Bel7402 cells after 4 days by MTT assay Cytotoxicity against human Bel7402 cells after 4 days by MTT assay	[PMID: 24359303]
BMDM	IC₅₀	15 μM Compound: 6	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
BV-2	IC₅₀	> 100 μM Compound: 26	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
DLD-1	IC₅₀	70 μM Compound: 4	Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay	[PMID: 15387639]
HBL-100	GI₅₀	> 100 μM Compound: 2	Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
HeLa	GI₅₀	49 μM Compound: 2	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
HepG2 2.2.15	EC₅₀	2.46 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion by ELISA	[PMID: 24549242]
HepG2 2.2.15	EC₅₀	3.94 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion by ELISA	[PMID: 24549242]
HepG2 2.2.15	IC₅₀	4.17 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production by quantitative RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production by quantitative RT-PCR analysis	[PMID: 24549242]
K562	IC₅₀	> 10 μM Compound: 22	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25710081]
KB	IC₅₀	> 10 μM Compound: 17	Cytotoxicity against human KB cells after 4 days by MTT assay Cytotoxicity against human KB cells after 4 days by MTT assay	[PMID: 24359303]
N9	IC₅₀	> 100 μM Compound: 31	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
SW1573	GI₅₀	54 μM Compound: 2	Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
T47D	GI₅₀	> 100 μM Compound: 2	Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
WiDr	GI₅₀	> 100 μM Compound: 2	Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]

In Vitro

Protocatechualdehyde (PCA) (50, 100 μM, 24/48 hours ) treated MCF-7 cells significantly decrease cell growth by 11% and 20% in 24 hours and by 22% and 27% in 48 hours, respectively^[2].
Protocatechualdehyde (50, 100 μM, 24 hours) treated MCF-7 cells are increased by 1.9-fold and 2.6-fold in the concentrations of 50 μM and 100 μM, respectively. PCA suppresses proliferation of estrogen receptor (ER)-positive (MCF-7) breast cancer cells, but not ER-negative (MDA-MB-231) breast cancer cells^[2].
Protocatechualdehyde (0, 100, 200 μM, 48 hours in HCT116 and SW480 cells) affects the enzyme activity of HDAC and observed that PCA treatment resulted in inhibition of HDAC activity in dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	Human breast cancer cell (MCF-7 and MDA-MB-231)
Concentration:	0, 5, 10, 25, 50, and 100 μM
Incubation Time:	24, 48 hours
Result:	Inhibited MCF-7 cells cell growth.

Apoptosis Analysis^[2]

Cell Line:	Human breast cancer cell (MCF-7 and MDA-MB-231)
Concentration:	0, 5, 10, 25, 50, and 100 μM
Incubation Time:	24, 48 hours
Result:	Increased apoptosis in MCF-7 cells.

Molecular Weight

138.12

Formula

C₇H₆O₃

CAS No.

139-85-5

Appearance

Solid

Color

Light yellow to brown

SMILES

O=CC1=CC=C(O)C(O)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (362.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	7.2401 mL	36.2004 mL	72.4008 mL
5 mM	1.4480 mL	7.2401 mL	14.4802 mL
10 mM	0.7240 mL	3.6200 mL	7.2401 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (248 KB) RP-HPLC (97 KB)

Handling Instructions (2659 KB)

References

[1]. Li S, et al. Evaluation of the Antibacterial Effects and Mechanism of Action of Protocatechualdehyde against Ralstonia solanacearum. Molecules. 2016 Jun 9;21(6). [Content Brief]

[2]. Choi J, et al. Anticancer activity of protocatechualdehyde in human breast cancer cells. J Med Food. 2014 Aug;17(8):842-8. [Content Brief]

[3]. Jeong JB, et al. Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 2013 Jan 4;430(1):381-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	7.2401 mL	36.2004 mL	72.4008 mL	181.0020 mL
	5 mM	1.4480 mL	7.2401 mL	14.4802 mL	36.2004 mL
	10 mM	0.7240 mL	3.6200 mL	7.2401 mL	18.1002 mL
	15 mM	0.4827 mL	2.4134 mL	4.8267 mL	12.0668 mL
	20 mM	0.3620 mL	1.8100 mL	3.6200 mL	9.0501 mL
	25 mM	0.2896 mL	1.4480 mL	2.8960 mL	7.2401 mL
	30 mM	0.2413 mL	1.2067 mL	2.4134 mL	6.0334 mL
	40 mM	0.1810 mL	0.9050 mL	1.8100 mL	4.5251 mL
	50 mM	0.1448 mL	0.7240 mL	1.4480 mL	3.6200 mL
	60 mM	0.1207 mL	0.6033 mL	1.2067 mL	3.0167 mL
	80 mM	0.0905 mL	0.4525 mL	0.9050 mL	2.2625 mL
	100 mM	0.0724 mL	0.3620 mL	0.7240 mL	1.8100 mL

Protocatechualdehyde Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Protocatechualdehyde139-85-5Catechaldehyde Protocatechuic aldehyde Rancinamycin IVReactive Oxygen SpeciesBacterialEndogenous MetaboliteInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Protocatechualdehyde (Synonyms: Catechaldehyde; Protocatechuic aldehyde; Rancinamycin IV)

Customer Review

Other Forms of Protocatechualdehyde:

Protocatechualdehyde Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Protocatechualdehyde Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Protocatechualdehyde Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report